Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder.

TitleAssociation of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder.
Publication TypeJournal Article
Year of Publication2014
AuthorsXylinas E, Cha EK, Khani F, Kluth LA, Rieken M, Volkmer BG, Hautmann R, Küfer R, Chen Y-T, Zerbib M, Rubin MA, Scherr DS, Shariat SF, Robinson BD
JournalJ Urol
Volume191
Issue3
Pagination830-41
Date Published2014 Mar
ISSN1527-3792
KeywordsAged, Antigens, Neoplasm, Antigens, Surface, Biomarkers, Tumor, Carcinoma, Transitional Cell, Cystectomy, Glypicans, Humans, Lymph Node Excision, Lymphatic Metastasis, Membrane Glycoproteins, Middle Aged, Neoplasm Grading, Neoplasm Proteins, Neoplasm Staging, RNA-Binding Proteins, Treatment Outcome, Urinary Bladder, Urinary Bladder Neoplasms
Abstract

PURPOSE: Oncofetal proteins are expressed in the developing embryo. Oncofetal protein expression correlates with the clinical outcome of nonmuscle invasive bladder urothelial carcinoma. IMP3, MAGE-A, glypican-3 and TPBG are oncofetal proteins that have not been well characterized in urothelial carcinoma of the bladder.

MATERIALS AND METHODS: We investigated the expression of these 4 proteins and their association with clinical outcomes using tissue microarrays from 384 consecutive patients treated with radical cystectomy between 1988 and 2003 at 1 academic center. We stained for IMP3, MAGE-A, glypican-3 and TPBG. Univariable and multivariable Cox regression analyses were done to evaluate the association of oncofetal protein expression with disease recurrence and cancer specific mortality.

RESULTS: IMP3, MAGE-A, glypican-3 and TPBG were expressed in 39.5%, 45%, 6% and 85% of urothelial bladder carcinomas, respectively. Expression was tumor specific and did not correlate with pathological features except for TPBG. At a median followup of 128 months 176 patients (46%) experienced disease recurrence, 175 (45.5%) had died of the disease and 96 (27.5%) had died of another cause. On univariable analysis IMP3 and MAGE-A expression was associated with an increased risk of disease recurrence (p <0.001 and 0.03) and cancer specific mortality (p = 0.004 and 0.03, respectively). On multivariable Cox regression analysis adjusted for the effects of standard clinicopathological features IMP3 and MAGE-A expression was independently associated with disease recurrence (p = 0.004, HR 1.55, 95% CI 1.15-2.11 and p = 0.02, HR 1.44, 95% CI 1.05-1.99, respectively) but not with cancer specific mortality.

CONCLUSIONS: Oncofetal proteins are commonly and differentially expressed in urothelial carcinoma of the bladder compared to normal urothelium. IMP3 and MAGE-A expression was associated with disease recurrence and cancer specific mortality but glypican-3 and TPBG expression was not.

DOI10.1016/j.juro.2013.08.048
Alternate JournalJ Urol
PubMed ID23994370
Related Faculty: 
Brian Robinson, M.D. Francesca Khani, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700